Natera Q4 prelim revenue beats on oncology tests boost

Natera's preliminary Q4 revenue rose 39% year-over-year, surpassing analyst expectations, driven by a 55% increase in oncology tests processed. The company anticipates a 35% revenue growth in 2025, exceeding previous forecasts by $40 million. Natera achieved record clinical MRD test volumes despite fewer sample processing days. Analysts maintain a "buy" rating on Natera, with a median 12-month price target of $257.50, reflecting a 9.9% upside from its recent closing price of $234.31. Further updates are expected at the J.P. Morgan Conference.